BIOCRYST PHARMACEUTICALS, INC. Increase (Decrease) in Contract with Customer, Liability
BIOCRYST PHARMACEUTICALS, INC. (BCRX) reported Increase (Decrease) in Contract with Customer, Liability of $10.79 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerLiability · last filed 2026-08-05
- BIOCRYST PHARMACEUTICALS, INC. increase (decrease) in contract with customer, liability for the quarter ending 2026-06-30 was $11.54M.
- BIOCRYST PHARMACEUTICALS, INC. increase (decrease) in contract with customer, liability for the quarter ending 2026-03-31 was -$749.00K.
- BIOCRYST PHARMACEUTICALS, INC. increase (decrease) in contract with customer, liability for the quarter ending 2025-06-30 was $0.00.
- BIOCRYST PHARMACEUTICALS, INC. increase (decrease) in contract with customer, liability for the quarter ending 2025-03-31 was $0.00.
- BIOCRYST PHARMACEUTICALS, INC. increase (decrease) in contract with customer, liability for fiscal 2025 was $0.00.
- BIOCRYST PHARMACEUTICALS, INC. increase (decrease) in contract with customer, liability for fiscal 2024 was $0.00.
- BIOCRYST PHARMACEUTICALS, INC. increase (decrease) in contract with customer, liability for fiscal 2023 was -$1.23M.
- BIOCRYST PHARMACEUTICALS, INC. increase (decrease) in contract with customer, liability for fiscal 2022 was -$109.00K, a 108.50% decline from fiscal 2021.
| Period end | Increase (Decrease) in Contract with Customer, Liability 3 month | Increase (Decrease) in Contract with Customer, Liability 6 month | Increase (Decrease) in Contract with Customer, Liability 9 month | Increase (Decrease) in Contract with Customer, Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | $11.54M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $10.79M 10-Q · filed 2026-08-05 | ||
| 2026-03-31 | -$749.00K 10-Q · filed 2026-05-06 | |||
| 2025-12-31 | $0.00 10-K · filed 2026-02-26 | |||
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $0.00 10-Q · filed 2026-08-05 | $0.00 derived: sum of 3 quarters · filed 2026-08-05 | $0.00 derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-06 | $0.00 derived: sum of 2 quarters · filed 2026-05-06 | $0.00 derived: sum of 3 quarters · filed 2026-05-06 | $0.00 derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $0.00 derived: sum of 3 quarters · filed 2026-02-26 | $0.00 10-K · filed 2026-02-26 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $0.00 derived: sum of 2 quarters · filed 2024-11-05 | $0.00 10-Q · filed 2024-11-05 | -$419.00K derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $0.00 10-Q · filed 2024-08-06 | -$419.00K derived: sum of 3 quarters · filed 2026-02-26 | -$1.76M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-07 | -$419.00K derived: sum of 2 quarters · filed 2026-02-26 | -$1.76M derived: sum of 3 quarters · filed 2026-02-26 | -$1.20M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | -$419.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$1.76M derived: sum of 2 quarters · filed 2026-02-26 | -$1.20M derived: sum of 3 quarters · filed 2026-02-26 | -$1.23M 10-K · filed 2026-02-26 |
| 2023-09-30 | -$1.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | -$776.00K derived: sum of 2 quarters · filed 2024-11-05 | -$811.00K 10-Q · filed 2024-11-05 | -$1.25M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | $570.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $535.00K 10-Q · filed 2024-08-06 | $97.00K derived: sum of 3 quarters · filed 2025-02-25 | $240.00K derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | -$35.00K 10-Q · filed 2024-05-07 | -$473.00K derived: sum of 2 quarters · filed 2025-02-25 | -$330.00K derived: sum of 3 quarters · filed 2025-02-25 | -$219.00K derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | -$438.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | -$295.00K derived: sum of 2 quarters · filed 2025-02-25 | -$184.00K derived: sum of 3 quarters · filed 2025-02-25 | -$109.00K 10-K · filed 2025-02-25 |
| 2022-09-30 | $143.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $254.00K derived: sum of 2 quarters · filed 2023-11-08 | $329.00K 10-Q · filed 2023-11-08 | $1.16M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $111.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $186.00K 10-Q · filed 2023-08-07 | $1.01M derived: sum of 3 quarters · filed 2024-02-27 | $1.07M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $75.00K 10-Q · filed 2023-05-08 | $901.00K derived: sum of 2 quarters · filed 2024-02-27 | $955.00K derived: sum of 3 quarters · filed 2024-02-27 | $1.10M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $826.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $880.00K derived: sum of 2 quarters · filed 2024-02-27 | $1.03M derived: sum of 3 quarters · filed 2024-02-27 | $1.28M 10-K · filed 2024-02-27 |
| 2021-09-30 | $54.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-04 | $202.00K derived: sum of 2 quarters · filed 2022-11-04 | $457.00K 10-Q · filed 2022-11-04 | $175.00K derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | $148.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-05 | $403.00K 10-Q · filed 2022-08-05 | $121.00K derived: sum of 3 quarters · filed 2023-02-27 | -$162.00K derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | $255.00K 10-Q · filed 2022-05-09 | -$27.00K derived: sum of 2 quarters · filed 2023-02-27 | -$310.00K derived: sum of 3 quarters · filed 2023-02-27 | -$662.00K derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | -$282.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | -$565.00K derived: sum of 2 quarters · filed 2023-02-27 | -$917.00K derived: sum of 3 quarters · filed 2023-02-27 | -$1.97M 10-K · filed 2023-02-27 |
| 2020-09-30 | -$283.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | -$635.00K derived: sum of 2 quarters · filed 2021-11-04 | -$1.69M 10-Q · filed 2021-11-04 | $211.00K derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | -$352.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | -$1.41M 10-Q · filed 2021-08-09 | $494.00K derived: sum of 3 quarters · filed 2022-02-28 | $494.00K derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | -$1.05M 10-Q · filed 2021-05-07 | $846.00K derived: sum of 2 quarters · filed 2022-02-28 | $846.00K derived: sum of 3 quarters · filed 2022-02-28 | |
| 2019-12-31 | $1.90M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $1.90M derived: sum of 2 quarters · filed 2022-02-28 | $1.90M 10-K · filed 2022-02-28 | |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | $0.00 10-Q · filed 2020-11-06 | ||
| 2019-06-30 | $0.00 10-Q · filed 2020-08-07 | |||
| 2018-12-31 | $21.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | -$79.00K derived: sum of 2 quarters · filed 2021-03-01 | -$7.08M 10-K · filed 2021-03-01 | |
| 2018-09-30 | -$100.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08 | -$7.10M 10-Q · filed 2019-11-08 | ||
| 2018-06-30 | -$7.00M 10-Q · filed 2019-08-08 | |||
| 2017-12-31 | -$1.72M 10-K · filed 2020-03-13 | |||
| 2016-12-31 | -$1.63M 10-K · filed 2019-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |